CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO MASTER MANUFACTURING SUPPLY AGREEMENTMaster Manufacturing Supply Agreement • February 23rd, 2023 • Travere Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “Amendment”), effective as of the November 14, 2022 (“Amendment Effective Date”), is made by and between Travere Therapeutics, Inc. (formerly known as Retrophin, Inc.) (“Client”), and STA Pharmaceutical Hong Kong Limited (“Supplier”). Client and Supplier may be hereinafter referred to individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • February 23rd, 2023 • Travere Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to License and Collaboration Agreement (the “Amendment”) is entered into as of October 5, 2022 (the “Amendment Effective Date”) by and between Travere Therapeutics Switzerland GmbH (formerly known as Orphan Technologies Limited) (“LICENSOR”) and Vifor (International) Ltd. (“LICENSEE”). LICENSOR and LICENSEE are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
